IRVINE, Calif., Nov. 1, 2022 /PRNewswire/ — Edwards Lifesciences (NYSE: EW) today announced that it has executed an accelerated share repurchase agreement (“ASR”) to repurchase $750 million of Edwards’ common stock. With this transaction, Edwards has repurchased more than $1.7 billion of shares in 2022. Under the terms of this ASR, Edwards will receive an initial delivery […]
Financial
Semler Reports Third Quarter and Year-to-Date 2022 Financial Results
2022 Q3 quarterly HIGHLIGHTS compared to the corresponding period of 2021: Revenue was $14.0 million, same as the prior year period Net income was $3.7 million, or $0.55 per basic share and $0.46 per diluted share, compared to $4.2 million, or $0.61 per basic share and $0.51 per diluted share Cash and cash equivalents at September 30, 2022 increased to $45.5 million from $35.9 million SANTA CLARA, […]
ViewRay Announces Third Quarter 2022 Results
DENVER, Nov. 1, 2022 /PRNewswire/ — ViewRay, Inc. (Nasdaq: VRAY) (the “Company”) today announced financial results for the third quarter ended September 30, 2022. Third Quarter 2022 Highlights Total revenue for the third quarter 2022 was approximately $26.5 million, primarily from four revenue units, compared to approximately $19.2 million, primarily from three revenue units, in the third […]
Acutus Medical Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CARLSBAD, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) — Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, granted equity awards on November 1, 2022 that were approved by the Compensation Committee of its Board of […]
CVRx Reports Third Quarter 2022 Financial and Operating Results
Third quarter 2022 revenue of $6.2 million, an 82% increase over prior year MINNEAPOLIS, Nov. 01, 2022 (GLOBE NEWSWIRE) — CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for […]
iRhythm Technologies Announces Third Quarter 2022 Financial Results
SAN FRANCISCO, Nov. 01, 2022 (GLOBE NEWSWIRE) — iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today reported financial results for the three months ended September 30, 2022. Third Quarter 2022 Financial Results Revenue of $103.9 million, a 21.6% […]
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on October 31, 2022 it granted stock options to purchase an aggregate of 202,500 shares of common stock to 20 new employees, whose employment commenced in October 2022, as a material inducement to […]
LEXEO Therapeutics Bolsters Cardiac Gene Therapy Leadership with New Executive Appointment and Formation of Scientific Advisory Board
Eric Adler, M.D., joins LEXEO as Chief Scientific Officer New Scientific Advisory Board comprised of molecular cardiology, cardiovascular imaging, cardiac gene-editing, and RNA biology experts NEW YORK, Nov. 02, 2022 (GLOBE NEWSWIRE) — LEXEO Therapeutics, Inc. (LEXEO), a clinical-stage biotech company advancing a pipeline of adeno-associated virus (AAV)-based gene therapy candidates […]
United Therapeutics Corporation Reports Third Quarter 2022 Financial Results
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended September 30, 2022. Total revenues in the third quarter of 2022 grew 16% year-over-year to $516.0 million, compared to $444.7 million in the third […]
Johnson & Johnson to Acquire Abiomed
Strengthens Johnson & Johnson’s MedTech Business with the Addition of Abiomed, a World-Leader in Heart Recovery Transaction to Bring Lifesaving Innovations to More Patients with Unmet Need Expected to Enhance Johnson & Johnson’s Near- and Long-Term Sales and Earnings Growth; Accretive to Adjusted Earnings beginning in 2024 Conference Call at 8:00 […]
Recent
Merit Medical to Participate in Upcoming Investors Conferences in September
Medtronic Endurant™ stent graft system first and only to receive CE-mark for updated rupture labeling
SinglePass Device Achieves 100% Technical Success and Zero Clinically Significant Bleeding Events in Multicenter Study Published in the Journal of Vascular and Interventional Radiology
Popular
- No commented posts yet